Optos (LON: OPTS)‘s stock had its “buy” rating reaffirmed by stock analysts at Canaccord Genuity in a report issued on Tuesday, ARN reports. They currently have a GBX 248 ($3.75) price target on the stock. Canaccord Genuity’s target price would suggest a potential upside of 95.66% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Nplus1 Brewin upgraded shares of Optos to a “hold” rating in a research note to investors on Wednesday, May 22nd. They now have a GBX 135 ($2.04) price target on the stock, down previously from GBX 150 ($2.27). Separately, analysts at N+1 Singer upgraded shares of Optos from a “sell” rating to a “hold” rating in a research note to investors on Wednesday, May 22nd. They now have a GBX 135 ($2.04) price target on the stock, down previously from GBX 150 ($2.27). Finally, analysts at Shore Capital Stockbrokers reiterated a “hold” rating on shares of Optos in a research note to investors on Thursday, May 16th.
One analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. Optos presently has a consensus rating of “Hold” and a consensus target price of GBX 206.33 ($3.12).
Optos (LON: OPTS) traded down 5.33% on Tuesday, hitting GBX 120.00. Optos has a 1-year low of GBX 106.75 and a 1-year high of GBX 230.59. The stock’s 50-day moving average is currently GBX 190.0. The company’s market cap is £86.2 million.
Optos Plc is a retinal imaging company. The Company’s medical devices produce ultra-widefield, high resolution digital images of approximately 82% of the retina in a single capture.